Cardiac-specific deletion of GCN5L1 promotes fatty liver disease in HFpEF
Bugga, P.; Mushala, B. A.; Stoner, M. W.; Manning, J. R.; Bhattarai, N.; Sharifi-Sanjani, M.; Vandevender, A.; Mooli, R. G.; Ramakrishnan, S. K.; Kaufman, B. A.; Shiva, S. S.; Happe, C. L.; Mullett, S. J.; Gelhaus, S. L.; Jurczak, M. J.; Scott, I.
Show abstract
The prevalence of cardiometabolic heart failure with preserved ejection fraction (HFpEF) continues to grow, representing over half of heart failure cases in the United States. As no specific medication for HFpEF exists, treatment guidelines focus on the management of comorbidities related to metabolic syndrome (e.g. obesity, diabetes, hypertension) that promote the disease1. These same comorbidities also drive pathology in non-cardiac tissues, and the links between cardiometabolic disease presentations in different organs are increasingly being recognized. Preclinical studies on the potential crosstalk between HFpEF and metabolic disease in the liver (e.g. metabolic dysfunction-associated liver disease; MASLD) have focused on how liver dysfunction may affect the heart, particularly through the release of secreted liver proteins. This may reflect the situation in the clinic, where incident MASLD is a risk factor for future HFpEF development. Here, in contrast to this developing paradigm of liver-initiated cardiac disease, we report for the first time a defect in cardiac metabolism related to the mitochondrial metabolic protein GCN5L1 that drives hepatic steatosis and MASLD in HFpEF.
Matching journals
The top 11 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Extracellular Matrix Abnormalities Contribute to Cardiac Insulin Resistance and Associated Dysfunction in Diet-induced Obese Mice 95%
- Adiponectin-receptor agonism prevents right ventricular tissue pathology in a mouse model of Duchenne muscular dystrophy 94%
- The SARS-CoV-2 Spike protein induces long-term transcriptional perturbations of mitochondrial metabolic genes, causes cardiac fibrosis, and reduces myocardial contractile in obese mice 93%
Similar papers in this journal
- A Slc5a6 Deficient Mouse Model Reveals a Metabolically Driven Dilated Cardiomyopathy with Therapeutic Potential for Vitamin-Based Intervention 94%
- Genetic Inhibition of Serum Glucocorticoid Kinase 1 Prevents Obesity-related Atrial Fibrillation 92%
- Extracellular Matrix Alterations in Chronic Ischemic Cardiomyopathy Revealed by Quantitative Proteomics 91%
Similar papers in this journal
- Intermittent Fasting Activates AMP-Kinase to Restructure Right Ventricular Lipid Metabolism and Microtubules in Two Rodent Models of Pulmonary Arterial Hypertension 95%
- With No Lysine Kinase 1 Promotes Right Ventricular Dysfunction Via Glucotoxicity 95%
- Apolipoprotein M attenuates anthracycline cardiotoxicity and lysosomal injury 92%
Similar papers in this journal
- A Remarkable Adaptive Paradigm Of Heart Performance And Protection Emerges In Response To The Constitutive Challenge Of Marked Cardiac-Specific Overexpression Of Adenylyl Cyclase Type 8 94%
- SIRT2 inhibition protects against cardiac hypertrophy and heart failure 93%
- Ryanodine receptor 2 inhibition reduces dispersion of cardiac repolarization, improves contractile function and prevents sudden arrhythmic death in failing hearts 93%
Similar papers in this journal
- Unrestrained fatty acid oxidation triggers heart failure in mice via cardiolipin loss and mitochondrial dysfunction 95%
- Liver-specific suppression of ANGPTL4 improves obesity-associated diabetes and mitigates atherosclerosis in mice 93%
- Pulmonary Arterial Hypertension Induces a Metabolic and Inflammatory Hepatopathy 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.